Bristol Myers' lung disease drug meets main goal in late-stage trial
12/10/2026 11:54
Bristol Myers' lung disease drug meets main goal in late-stage trial Oct 12 (Reuters) - Bristol Myers Squibb BMY.N said on Monday its experimental drug met the main goal of a late-stage trial in patients with idiopathic pulmonary fibrosis, a serious lung-scarring disease.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal Muhammed)
Recent news on Bristol-Myers Squibb
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Bristol Myers Squibb To Showcase Next-Generation Cancer Modalities And Leadership Across Solid Tumors At Esmo 2026
US RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Healthcare stocks rally as investors seek safety amid tech debt worries
AstraZeneca strikes $40 million AI drug discovery deal with insitro